Janet Brunner

A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing

Dolores Grosso, Matthew Carabasi, Joanne Filicko-O’Hara et al. · Blood · 2011 · 77 citations · Full text

Medicine, Hematology, Immunology +14

Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study

G. L. Phillips, Barry Meisenberg, Donna Reece et al. · Biology of Blood and Marrow Transplantation · 2004 · 71 citations · Full text

Medicine, Hematology, Oncology +13

Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients

T. Cerny, Serge Leyvraz, Thomas von Briel et al. · Annals of Oncology · 1999 · 38 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +12

Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches

Thea M. Friedman, Gàbor Varadi, Deborah D. Hopely et al. · Biology of Blood and Marrow Transplantation · 2001 · 30 citations · Full text

Medicine, Hematology, Immunology +17

Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma

G. L. Phillips, Barry Meisenberg, Donna Reece et al. · Bone Marrow Transplantation · 2004 · 24 citations

Medicine, Hematology, Oncology +17